Investment Group Discloses 7.1% Stake Post-IPO, Includes Board Member

summarizeSummary

Dimension Management, L.P. and its affiliates, including a board member, disclosed a 7.1% ownership stake in Odyssey Therapeutics, representing an investment of over $45 million following the company's IPO.

check_boxKey Events

• Significant Ownership Stake

  Dimension Management, L.P. and its affiliates reported a 7.1% beneficial ownership stake in Odyssey Therapeutics, totaling 3,333,516 shares.

• Substantial Investment Value

  The disclosed investment by the reporting group totals over $45 million, acquired through warrant exercises, preferred stock conversions, and a direct purchase in the IPO.

• Board Representation

  Nan Li, a member of the reporting group, currently serves on Odyssey Therapeutics' Board of Directors, indicating active involvement.

• Post-IPO Disclosure

  The stake was established on May 8, 2026, coinciding with the closing of the company's initial public offering.

auto_awesomeAnalysis

This Schedule 13D filing reveals that Dimension Management, L.P. and its affiliates, including board member Nan Li, have established a significant 7.1% beneficial ownership stake in Odyssey Therapeutics. The investment, totaling over $45 million, was primarily acquired through pre-IPO conversions and a direct purchase in the recent initial public offering. This disclosure, coming shortly after the company's IPO, represents a strong vote of confidence from a substantial institutional investor with direct board representation, signaling long-term commitment.